Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies

What Was Tested

The paper reports a study of Elagolix (non-peptide) in the context of endometriosis, published as a randomized controlled trial.

Who Took Part

The abstract describes 12 women taking part.

PubMed indexes the participants as teenagers, young adults, adults and middle-aged adults, women only.

Safety assessments included adverse events, clinical laboratory tests, and endometrial and bone mineral density assessments.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Elagolix (non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the women and researchers unaware of who received Elagolix (non-peptide).

The comparison arm used a placebo, so changes seen with Elagolix (non-peptide) could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Dysmenorrhea, Dyspareunia, Endometriosis, Gonadotropin-Releasing Hormone, Hot Flashes, Hydrocarbons, Fluorinated and Pelvic Pain.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Elagolix (non-peptide) in 12 women in people with endometriosis.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Obstetrics and gynecology), a journal based in United States.

More context: the Elagolix (non-peptide) compound page, Endometriosis research.